Twi Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TWI PHARMS, and when can generic versions of TWI PHARMS drugs launch?
TWI PHARMS has twenty-nine approved drugs.
There is one US patent protecting TWI PHARMS drugs. There is one tentative approval on TWI PHARMS drugs.
There is one patent family member on TWI PHARMS drugs in one country and one hundred and twenty-eight supplementary protection certificates in sixteen countries.
Summary for Twi Pharms
| International Patents: | 1 |
| US Patents: | 1 |
| Tradenames: | 26 |
| Ingredients: | 23 |
| NDAs: | 29 |
Drugs and US Patents for Twi Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Twi Pharms | DILTIAZEM HYDROCHLORIDE | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 205231-005 | Aug 30, 2018 | AB3 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Twi Pharms | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 203126-002 | Apr 3, 2014 | AB2 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Twi Pharms | DICYCLOMINE HYDROCHLORIDE | dicyclomine hydrochloride | TABLET;ORAL | 216782-001 | Jun 1, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-002 | May 19, 1988 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-005 | Apr 29, 1993 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Twi Pharms | FORFIVO XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022497-001 | Nov 10, 2011 | RX | Yes | Yes | 7,674,479 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Twi Pharms | DILTIAZEM HYDROCHLORIDE | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 205231-001 | Aug 30, 2018 | AB3 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Twi Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Twi Pharms | ZESTRIL | lisinopril | TABLET;ORAL | 019777-004 | May 19, 1988 | 4,374,829*PED | ⤷ Try a Trial |
| Twi Pharms | TENORETIC 50 | atenolol; chlorthalidone | TABLET;ORAL | 018760-002 | Jun 8, 1984 | 3,934,032 | ⤷ Try a Trial |
| Twi Pharms | TENORETIC 50 | atenolol; chlorthalidone | TABLET;ORAL | 018760-002 | Jun 8, 1984 | 3,663,607 | ⤷ Try a Trial |
| Twi Pharms | NAPRELAN | naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 020353-003 | Jan 5, 1996 | 5,637,320 | ⤷ Try a Trial |
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | 3,663,607 | ⤷ Try a Trial |
| Twi Pharms | TENORETIC 100 | atenolol; chlorthalidone | TABLET;ORAL | 018760-001 | Jun 8, 1984 | 3,663,607 | ⤷ Try a Trial |
| Twi Pharms | NAPRELAN | naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 020353-001 | Jan 5, 1996 | 5,637,320 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TWI PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 450 mg | ➤ Subscribe | 2013-02-28 |
International Patents for Twi Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008038155 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Twi Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1412357 | PA2008013,C1412357 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716 |
| 1506211 | 179 5017-2014 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116 |
| 1411900 | SPC/GB11/015 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 0984957 | SPC/GB11/013 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 1761528 | CA 2014 00055 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TRAMETINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER TRAMETINIBDIMETHYLSULFOXID; REG. NO/DATE: EU/1/14/931/01-06 20140630 |
| 1532149 | CA 2013 00001 | Denmark | ⤷ Try a Trial | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720 |
| 0253310 | SPC/GB95/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
